Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Diamondback Energy Inc (FANG) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance

Diamondback Energy IncTrade
IDEXX Laboratories, Inc.Trade

Price performance (Past 24H)

Key statistics

Diamondback Energy Inc vs IDEXX Laboratories, Inc. — how do they compare? Diamondback Energy Inc trades at $199.23 (market cap $56.48B), while IDEXX Laboratories, Inc. trades at $571 (market cap $46.22B). The key difference: Diamondback Energy Inc is the larger of the two by market cap, and Diamondback Energy Inc pays a 2.18% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.

FANGIDXX
Market Cap
$56.48B$46.22B
Sector
EnergyHealth
52-Week High
$213.69$766.68
52-Week Low
$134.53$526.44
Enterprise Value
$68.63B$47.12B
Dividend Yield
2.18%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Diamondback Energy Inc

Diamondback Energy (FANG) trades at $200.97, up 1.01% today, with bullish technical signals and strong earnings beats in Q1 and Q2 2026. The stock benefits from high oil prices, production growth, and a 90% analyst buy rating. Recent news highlights Q2 earnings surpassing estimates, driven by operational efficiency and raised 2026 output guidance. Cash flow from operations improved to $8.76 billion in 2025, though net income margin declined to 8.64%.

The outlook is positive, with a consensus price target of $236.63 offering ~18% upside, supported by debt reduction and Permian Basin strength. Risks include oil price volatility, margin pressure from rising costs, and geopolitical supply disruptions affecting global markets. Institutional inflows, like Balefire LLC's recent purchase, reinforce confidence in growth prospects.

IDEXX Laboratories, Inc.

IDEXX Laboratories (IDXX) trades at $570.58, down 4.23% over 24 hours, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $4.27 surpassing the $3.94 expectation. Revenue growth remains robust, supported by a 74.21% ROE and expanding diagnostic offerings. Recent news highlights product expansion, including a dual-species cardiac test, reinforcing its market leadership in veterinary diagnostics.

The outlook is positive, driven by durable competitive advantages and international growth potential. However, elevated valuation multiples and competitive pressures pose risks. Analyst consensus is bullish with a $683.33 price target, suggesting significant upside from current levels, though investors should monitor execution on guidance and macroeconomic headwinds.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Diamondback Energy Inc

Diamondback Energy is an independent oil and gas producer in the United States. The company operates exclusively in the Permian Basin. At the end of 2021, the company reported net proven reserves of 1.8 billion barrels of oil equivalent. Net production averaged about 375,000 barrels per day in 2021, at a ratio of 60% oil, 20% natural gas liquids, and 20% natural gas.

Read more on FANG

About IDEXX Laboratories, Inc.

Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.

Read more on IDXX